

Curriculum Vitae

Kristin Bamber Highland, M.D. M.S.C.R.

Assistant Professor of Medicine

Division of Pulmonary, Critical Care Allergy and Sleep Medicine

96 Jonathan Lucas Street, Suite 812 CSB

PO Box 250630

Charleston, SC 29425

(843) 792-3712 (office)

(843) 792-0732 (fax)

highlkb@musc.edu

VISION: To be an expert clinician and clinical/ translational researcher for patients with pulmonary manifestations of rheumatic disease, with an emphasis on pulmonary hypertension and interstitial lung disease

EDUCATION

Indiana University, Bloomington, IN	8/86-5/89
Bachelor of Arts in Biology and Chemistry	
Indiana University School of Medicine	
Bloomington, IN	8/89-6/91
Indianapolis, IN	7/91-5/93
Medical Doctorate	
Medical University of South Carolina, Charleston, SC	8/00-5/06
Master of Science in Clinical Research	

Internship:

Medical University of South Carolina, Charleston, SC	
Family Medicine	7/93-1/94
Internal Medicine	2/94-9/94

Residency:

Medical University of South Carolina, Charleston, SC	
Internal Medicine	10/94-10/96

Fellowships:

Medical University of South Carolina, Charleston, SC	
Pulmonary and Critical Care Medicine,	7/99-6/02
Allergy and Clinical Immunology	
Rheumatology and Immunology	7/03-6/06

APPOINTMENTS

Assistant Professor Department of Medicine Medical University of South Carolina Charleston, SC	7/02-6/08
Associate Member of the Graduate Faculty Medical University of South Carolina Charleston, SC	10/04-present
Associate Professor	7/08-present

Administrative appointments:

Associate Director, Adult Cystic Fibrosis Center Medical University of South Carolina Charleston, SC	7/02-6/05
Director, Pulmonary Hypertension Program Medical University of South Carolina Charleston, SC	7/05-present
Director, Pulmonary Clinic MUSC Trustees' Leadership Academy	8/07-present 7/08-6/09

HOSPITAL PRIVLEDGES

Medical University of South Carolina, Charleston, SC	7/99-present
Charleston Memorial Hospital, Charleston, SC	7/99-present
Ralph H. Johnson VA Hospital, Charleston, SC	7/99-present
Kindred Hospital, Charleston, SC	7/99-12/06

MILITARY SERVICE

United States Air Force, Captain Active Duty	10/96-1/99
Inactive Reserves	2/99-10/03

CERTIFICATION

Internal Medicine	8/1997
Pulmonary Disease	11/2001
Critical Care	11/2002
Rheumatology	Board Eligible
BLS	
ACLS	

LICENSURE

South Carolina #17587	10/94-present
Oklahoma #19997	0/96-10/99

PROFESSIONAL MEMBERSHIPS AND ACTIVITIES

National Societies:

American College of Chest Physicians, Fellow
American College of Physicians, Fellow
American College of Rheumatology
American Medical Association
American Thoracic Society
Pulmonary Hypertension Association

Local Societies:

South Carolina Medical Association

COMMITTEE ASSIGNMENTS

Respiratory Care Committee	2002-2006
South Carolina Board of Medical Examiners, Columbia, SC	
Diversity in Medicine Committee	2003-present
Medical University of South Carolina, Charleston, SC	
Interstitial Lung Disease Network, Steering Committee	2004-2008
American College of Chest Physicians	
Affiliate Network, Steering Committee	2006-present
American College of Chest Physicians	
Search Committee: Division Director of Infectious Diseases	2006-2007

HONORS AND AWARDS

Clinical Research Curriculum Award (K30)	6/01-03
Young Investigator Award	2002
American College of Chest Physicians	
Young Investigator Award	2003
AMGEN	
National Institutes of Health Clinical Research Loan Repayment Program	2003-2005
Best Doctors	2004-2008
Faculty Excellence Award: Nomination	2006
Medical University of South Carolina	
Travel Bursary	2006
European League Against Rheumatism (EULAR)	
Developing Scholar: Nomination	2006
Medical University of South Carolina	
Travel Scholarship:	2006
Scleroderma Clinical Trials Consortium (Tokyo, Japan)	
Excellence in Teaching Award: Nomination	2008

EDUCATIONAL ACTIVITIES

Undergraduate Medical Education	
Preceptor, Physical Diagnosis	1/01-present

Thesis Committee Member and Advisor		
Rebecca Boehm , Masters in Biostatistics		7/03-10/05
"On the Utility of Stochastic Models of Chronic Obstructive Pulmonary Disease"		
Margaret Garin , Southeastern Predoctoral Training in Clinical Research/T-32 Student		7/06-6/08
"Clinically Meaningful 6 Minute Walk Change in Pulmonary Arterial Hypertension"		
Faye Hant , Masters of Science in Clinical Research		1/07-6/08
"Change in SP-D and KL-6 after treatment of Scleroderma Interstitial Lung Disease with Cyclophosphamide"		
Clinical/Clinical Research Mentor		
Meena Kalluri , Pulmonary Fellow		1/07-6/08
Clinic Supervisor		
Nicholas Pastis		7/04-6/05
Brian Zeno		7/05-6/06
Emergency Medicine Lecture Series		7/04-present
Lecturer		
3 rd Year Medical Students' Core Curriculum Lecture Series		7/02-present
Lecturer		
Pulmonary Fellow Core Curriculum Lecture Series		7/02-present
Lecturer		
Supervision of students, residents and fellows in clinical setting		7/02-present
Medical Knowledge Self-Assessment Program		5/06
Pretested multiple choice questions for 14 th edition		
Moderator		
CHEST 2006, Salt Lake City, UT		10/06
Interstitial Lung Disease Case Reports.		
Diffuse Lung Disease Case Reports		
CHEST 2007, Chicago, IL		10/07
Interstitial Lung Disease Case Reports		
Pulmonary Hypertension Original Investigation		
Pulmonary Hypertension Case Reports		
Vasculitis Case Reports		
CHEST 2008, Philadelphia, PA		10/08
Interstitial Lung Disease Case Reports		
Pulmonary Hypertension Case Reports		
Judge		
Student Research Day, MUSC, Charleston, SC		10/06

CLINICAL ACTIVITIES:

2002-2003

Clinic:	2 ½ days/week
Pulmonary Wards:	2 month
MICU:	3 months

Pulmonary Consults:	2 ½ months
2003-2004	
Clinic:	4 ½ days/week
Pulmonary Wards:	4 months
MICU:	1 month
Pulmonary Consults:	2 months
Rheumatology Consults:	1 month
2004-2005	
Clinic:	4 ½ days/week
Pulmonary Wards:	3 months
MICU:	2 months
Pulmonary Consults:	1 ½ months
Rheumatology Consults	1 month
Kindred Hospital	1 month
2005-2006	
Clinic:	4 ½ days/week
Pulmonary Wards:	1 month
MICU:	2 months
Pulmonary Consults:	1 month
Rheumatology Consults:	1 month
2006-2007	
Clinic:	3 ½ days/week
Pulmonary Wards:	2 months
MICU:	2 months
Pulmonary Consults:	2 ½ months
2007-2008	
Clinic:	4 ½ days/week
MICU:	3 months
Pulmonary Consults:	1 month
2008-2009	
Clinic	4-5 ½ days/week
MICU:	2 months
Pulmonary Consults	1 month
Wards	2 weeks

PRESENTATIONS:

National and International:

1. The role of collagen vascular disease in screening for early diagnosis of interstitial lung disease. CHEST Interstitial and Diffuse Lung Disease Network Consensus Workshop. March, 2003.
2. Supraesophageal Complications of Gastroesophageal Reflux Disease. Sunrise Seminar. American Thoracic Society, Seattle WA May 2003

3. Two "Routine" Patients with Pulmonary Arterial Hypertension and Scleroderma. United Therapeutics Corporation's PAH Symposium: From Bench to Bedside and Beyond. St. Thomas, USVI. December 2003
4. The Role of Thrombin in Scleroderma Interstitial Lung Disease. VIII International Workshop on Scleroderma Workshop, Cambridge, England, July 2004
5. Highland KB, Strange C, Mazur J, Simpson KN . A Preliminary Decision Analysis in Pulmonary Arterial Hypertension. VIII International Workshop on Scleroderma Workshop, Cambridge, England, July 2004
6. Approach to the Evaluation and Diagnosis of Interstitial Lung Disease in Patients with Connective Tissue Disease. Bialowieza, Poland, October 2004
7. Pulmonary Function Testing in Scleroderma. 1st EULAR Course on Scleroderma. Budapest, Hungary, January 2005
8. Overview of Scleroderma Lung Disease. Scleroderma Foundation 2005 National Conference, Boston, MA, June 2005
9. Shedding Light on Pulmonary Arterial Hypertension: Epidemiology and pathobiology of pulmonary arterial hypertension, Atlanta, GA. September 2005
10. Conventional Immunomodulatory Therapy for ANCA-associated Vasculitis. CHEST 2005, Montreal Canada, November, 2005
11. Scleroderma Lung Disease, American Thoracic Society, San Diego, CA May 2006
12. Difficult Management Issues in Sarcoidosis: Pulmonary Hypertension, American Thoracic Society, San Diego CA, May 2006
13. Pulmonary Hypertension, Today and Tomorrow: At Risk Populations in PAH: How Do You Classify Your Patients? Charlotte, NC October 2006
14. Treating Pulmonary Hypertension in Interstitial Lung Disease. CHEST 2006, Salt Lake City, UT, October 2006
15. Detection and Management of Pulmonary Hypertension Associated with Collagen Vascular Disease. CHEST 2006, Salt Lake City, UT, October 2006
16. Rheumatic Lung Disease and Reproduction. CHEST 2006, Salt Lake City, UT, October, 2006.

17. Conventional Therapy for Vasculitis in 2006. CHEST 2006, Salt Lake City, UT, October 2006
18. Dosing and Monitoring of Biological Agents. CHEST 2006, Salt Lake City, UT, October 2006
19. Pulmonary Function Testing in Scleroderma:101. 2nd EULAR Course on Scleroderma. Bad Nauheim, Germany, January 2007
20. ANCA-Associated Vasculitis [Conventional] Management of the Patient with Vasculitis in 2008. CHEST 2008, Philadelphia, PA, October 2008.
21. Update on Scleroderma Interstitial Lung Disease. (ACCP ILD-Network keynote speaker) CHEST 2008, Philadelphia, PA, October 2008.

Local:

1. Chronic Dyspnea in a 12-Year-Old with a Normal Chest X-ray. Eleventh Charleston Pulmonary and Critical Care Symposium, March 2001.
2. An Unusual Case of Seamstress Lung. Case Report and Literature Review of Giant Cell Interstitial Pneumonitis from Cobalt. South Carolina ACP-ASIM. September 2001.
3. An Unusual Case of Seamstress Lung. Case Report and Literature Review of Giant Cell Interstitial Pneumonitis from Cobalt. Twelfth Charleston Pulmonary and Critical Care Symposium, Charleston, SC March 2002
4. Nosocomial pneumonia. Review of 2002 CDC guidelines for preventing pneumonia. South Carolina Infection Control Society. October 2002.
5. Mechanical Ventilation, Weaning, and Sedation. Hartsville Medical Center, January 2003
6. Supraesophageal Complications of Gastroesophageal Reflux Disease. Thirteenth Charleston Pulmonary and Critical Care Symposium, Charleston, SC, March 2003
7. Supraesophageal Complications of Gastroesophageal Reflux Disease. Airways Challenges. Charleston, SC January, 2003
8. Pulmonary Arterial Hypertension. South Carolina Critical Care Nursing Association, Spartanburg, SC May 2003
9. Pulmonary Arterial Hypertension: 101. Airways Challenges. Charleston, SC January 2004

10. Pulmonary Manifestations of the Connective Tissue Diseases. Fourteenth Charleston Pulmonary and Critical Care Symposium, Charleston, SC March 2004.
11. Decisions in Pulmonary Arterial Hypertension. South Carolina Rheumatism Society, Charleston, SC April 2004
12. Epoprostenol, Treprostinil and PH: Where and When to Use? MUSC Pulmonary Hypertension Symposium: Suspicion, Diagnosis and Optimal Management. Charleston, SC, October, 2004
13. Pharmacoeconomics and Quality of Life in PH. MUSC Pulmonary Hypertension Symposium: Suspicion, Diagnosis and Optimal Management. Charleston, SC, October, 2004
14. PAH Secondary to Systemic Sclerosis. MUSC Pulmonary Hypertension Symposium: Suspicion, Diagnosis and Optimal Management. Charleston, SC, October, 2004
15. Update on Pulmonary Hypertension. Fifteenth Charleston Pulmonary and Critical Care Symposium, Charleston, SC March 2005.
16. Not Your Average Wheeze: two cases of eosinophilic myocarditis from Churg Strauss Syndrome. South Carolina Rheumatism Society, March 2005
17. Pulmonary Hypertension in the Connective Tissue Diseases. South Carolina Pulmonary Hypertension Support Group. Columbia, S.C. October, 2005.
18. Pulmonary Arterial Hypertension. South Carolina Academy of Physician Assistants. Kiawah Island, SC. October, 2005.
19. Novel Therapies in ANCA-Associated Vasculitis. Wegener's Support Group, Columbia, SC. November, 2005
20. ILD in Connective Tissue Disease. Sixteenth Charleston Pulmonary and Critical Care Symposium, Charleston, SC, April 2006
21. ANCA-Associated Vasculitis, Sixteenth Charleston Pulmonary and Critical Care Symposium, Charleston, SC, April 2006
22. Pulmonary Manifestations of Rheumatic Disease. University of South Carolina Department of Medicine Grand Rounds, Columbia, SC, October 2006
23. Pulmonary Hypertension in the Connective Tissue Diseases. Carolina Rheumatology Fellow's Symposium, Charleston, SC, January 2007

24. Overview of Pulmonary Arterial Hypertension. Seventeenth Charleston Pulmonary and Critical Care Symposium, Kiawah Island, SC April 2007.
25. Treatment of Pulmonary Arterial Hypertension. Seventeenth Charleston Pulmonary and Critical Care Symposium, Kiawah Island, SC April 2007.
26. Management of Right Heart Failure and Pulmonary Hypertension in the Intensive Care Unit, Eighteenth Charleston Pulmonary and Critical Care Symposium, Charleston, SC March 2008
27. The Rheumatologist's Perspective on Pulmonary Arterial Hypertension. Rheumatology Grand Rounds, University of North Carolina, Chapel Hill, NC, September 2008

Intramural:

1. Cryptococcal Pleural Effusions, case report and literature review. Pulmonary Division Grand Rounds, MUSC, Charleston, SC, August 1999.
2. Diffuse Pan Bronchiolitis, case report and literature review. Pulmonary Division Grand Rounds, MUSC, Charleston, SC October 1999.
3. Chronic Beryllium Disease, case report and literature review. Pulmonary Division Grand Rounds, MUSC, Charleston, SC February 2000.
4. Respiratory Failure from Infectious Mononucleosis, case report and literature review. Pulmonary Division Grand Rounds, MUSC, Charleston, SC March 2000.
5. Thymoma, case report and literature review. Pulmonary Division Grand Rounds, MUSC, Charleston, SC June 2000.
6. Interstitial Lung Disease. Internal Medicine Noon Conference. February 2003.
7. Pulmonary Arterial Hypertension, Medical Grand Rounds, Medical University of South Carolina, Charleston, SC, September 2003
8. Diffuse Alveolar Hemorrhage. Rheumatology Division Rounds. MUSC, Charleston, SC, October 2003
9. Getting Rid of Evil Humors. (Apheresis) Rheumatology Division Rounds. MUSC, Charleston, SC, October 2003

10. A 72-Year-Old White Female with Rheumatoid Arthritis and Chronic Cough (Felty's Syndrome). Rheumatology Division Rounds. MUSC, Charleston, SC, April 2004
11. Not Your Average Wheeze (Churg Strauss Syndrome). Rheumatology Division Rounds. MUSC, Charleston, SC April 2004
12. Endothelin Science. Rheumatology Division Rounds. MUSC, Charleston, SC, July 2004
13. Interpretation of Arterial Blood Gasses. Internal Medicine Noon Conference, Charleston, SC, July 2004
14. Respiratory Failure, Internal Medicine Noon Conference, Charleston, SC, July 2004
15. Respiratory Failure, Respiratory Therapy Conference, Charleston, SC, August 2004.
16. Interpretation of Arterial Blood Gasses. Internal Medicine Noon Conference, Charleston, SC, July 2004
17. Update on Pulmonary Arterial Hypertension. Medicine Grand Rounds, Medical University of South Carolina, Charleston, SC August 2005
18. Celiac Sprue. Rheumatology Division Rounds, MUSC, Charleston, SC. September 2005
19. Update on Pulmonary Hypertension. Internal Medicine Noon Conference, Charleston, SC, February 2007
20. Interpretation of Arterial Blood Gasses. Internal Medicine Noon Conference, Charleston, SC, July 2007
21. Update on Pulmonary Arterial Hypertension, Internal Medicine Noon Conference, Charleston, February 2008

EDITORIAL WORK

Editorial Board

Advances in Pulmonary Hypertension 1/1/07-12/1/08

Associate Editor

Advances in Pulmonary Hypertension 1/1/09-present

Guest Editor

Advances in Pulmonary Hypertension
Clinics in Chest Medicine

2008; volume 7
2010; volume X

Peer Reviewer

American Journal of Medicine
American Journal of Medical Sciences
Annals of Internal Medicine
Annals of Rheumatic Diseases
Arthritis Care and Research
CHEST
Clinica Chimica Acta
Clinical Pulmonary Medicine
Future Medicine
Intensive Care Medicine
JAMA
Journal of Musculoskeletal Medicine
Journal of Respiratory Diseases
Mayo Clinic Proceedings
Respiratory Medicine
Respiratory Care

GRANTS

Peroxisome proliferator-activated receptor gamma activity in scleroderma.
Multidisciplinary Clinical Research Center for Rheumatic Diseases. 2005-2006:
\$50,000

CONTRACTS

Principal Investigator:

Pulmonary Arterial Hypertension Quality Enhancement Research Initiative
(PAHQuERI), 2006-present: **\$37,500**

Effects of combination of bosentan and sildenafil versus sildenafil monotherapy
on morbidity and mortality in symptomatic patients with pulmonary arterial
hypertension: A multicenter, double-blind, randomized, placebo-controlled,
parallel group, prospective, event driven Phase IV study. (Compass II) Actelion,
Pharmaceuticals, Inc, 2006-present: **\$412,500**

A 16-Week, International, Multicenter, Double-Blind, Randomized, Placebo-
Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained
Release Tablets in Combination with an Endothelin Receptor Antagonist and/or a
Phosphodiesterase-5 Inhibitor in Subjects with Pulmonary Arterial Hypertension.
(TDE-PH-301) United Therapeutics, Inc 2006-2008: **\$85,975**

A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-
Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained

Release Tablets in Subjects with Pulmonary Arterial Hypertension (TDE-PH-302)
United Therapeutics, Inc 2006-2008: **\$41,600**

An Open-Label Extension Trial of UT-15C in Subjects with Pulmonary Arterial
Hypertension (TDE-PH-304) United Therapeutics, Inc 2006-2008 **\$55,225**

A Pharmacokinetic Study of UT-15C in Subjects with pulmonary Arterial
Hypertension (TDE-PH-306) United Therapeutics, Inc 2006-2008 **\$66,388**

An Evaluation of Biomarkers and Genetics in Subjects with Pulmonary Arterial
Hypertension (TDE-PH-307) United Therapeutics, Inc 2006-2008

Registry To Evaluate Early And Long-term PAH Disease Management (REVEAL
Registry™). CoTherix, Inc. 2006-present; **\$125,000**

Web Based PH Training 2006

Encysive Pharmaceuticals: **\$10,000**

CoTherix, Inc: **\$15,000**

Actelion Pharmaceuticals: **\$30,000**

Co-Investigator:

A Phase III, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy
Study of Investigational Endothelin Receptor Antagonist (ERA) Treatment, with
an Open-Label Bosentan (Tracleer®) Arm, in Patients with Pulmonary Arterial
Hypertension (PAH). Encysive, L.P. 2004-2005

An Open-Label Study to Evaluate the Long-Term Safety of Sitaxsentan Sodium
Treatment with a Bosentan Arm in Patients with Pulmonary Arterial
Hypertension. Encysive, L.P. 2004-2005

A Long-Term, Open-Label Study to Evaluate the Safety of Sitaxsentan Sodium
Treatment in Patients with Pulmonary Arterial Hypertension. Encysive, L.P.
2004-2005

A Double-Blind Safety and Efficacy Study of Sitaxsentan Sodium Treatment in
Patients with Pulmonary Arterial Hypertension /Who Have Failed Bosentan
Therapy. Encysive, L.P. 2004-2005

Inhaled Iloprost for Sarcoidosis Associated Pulmonary Hypertension. CoTherix,
Inc. **\$61,998**

Ambrisentan for Sarcoidosis Associated Pulmonary Hypertension. Gilead
Sciences

Medical Monitor:

Respiratory-gated PET/CT for evaluation of the small (4-10 mm) indeterminate pulmonary nodule 2007-present

Molecular markers of malignancy compared to histology in bronchial samples identified using narrow band imaging (NBI) bronchoscopy or white-light bronchoscopy for evaluation of normal, pre-malignant and malignant airways disease. 2007-present

PUBLICATIONS

Abstracts:

1. Highland KB, Retalis P, Coppage L, Schabel SI, and Judson MA. There an Anatomic Explanation for Chest Pain in Patients with Pulmonary Sarcoidosis? 92nd International Conference of the American Thoracic Society, New Orleans, LA, 1996
2. Highland KB, Flume PA. A "Story" of a Woman with Cystic Fibrosis. Adult Clinical Fellows Session. Fourteenth Annual North American Cystic Fibrosis Conference. November 2000.
3. Highland KB, Strange C. Demographics of Interstitial Lung Disease at a Tertiary Medical Center. 97th International Conference of the American Thoracic Society, San Francisco, CA, 2001.
4. Highland KB, Frye MD, Strange C. The demographics and sleep characteristics of hospitalized patients referred for overnight polysomnography. Chest 2001; 120:301S.
5. Highland KB, Strange C, Heffner JE. Inhaled Glucocorticoids and COPD, a meta-analysis. Chest 2002, San Diego, CA. November 2002. (**Winner of Young Investigator Award**)
6. Highland KB. Diffuse Alveolar Hemorrhage, AMGEN Young Investigator's Forum, Rheumatology on the Beach, San Destin, FL, September 2003 (**Winner of Young Investigator Award**)
7. Highland KB, Strange CB, Simpson KN. Effectiveness and Economic Impact of Treating Pulmonary Hypertension (PAH): A Decision-Analysis Comparing Epoprostenol, Treprostinil, and Bosentan. American Journal of Respiratory and Critical Care Medicine 2003; 167: A273
8. Boehm RS, Simpson KN, Highland KB. A Decision-Analysis of Inhaled Corticosteroids in COPD. American Journal of Respiratory and Critical Care Medicine 2004;169:A518 (Poster discussion)
9. Ford DW, Highland KB. Toluene Associated Pulmonary Hypertension Requiring Chronic Prostaglandin Therapy. Chest 2004; 126:956S-957S.

10. Bogatkevich GS, Ludwicka-Bradley A, Highland K, Singleton B, Nietert PJ, Shaftman S, Silver RM. Differences in cytokine composition in bronchoalveolar lavage fluid among African-American and Caucasian populations: implications for scleroderma lung disease. *Arthritis and Rheumatism* 2005
11. Highland KB, Silver RM, Bogatkevich G, Gilkeson G. Peroxisome proliferator-activated receptor gamma activity in scleroderma interstitial lung disease. *Annals of Rheumatic Diseases*. 2006; 65(suppl II):393 (Presented at Annual European Congress of Rheumatology EULAR 2006, Amsterdam, Netherlands, June 2006; **Winner of travel bursary**)
12. Highland KB, Strange C, Girgis R, Black C. Comparison of sitaxsentan and bosentan in pulmonary arterial hypertension associated with connective tissue disease. *Annals of Rheumatic Diseases*. 2006; 65 (Suppl II):393 (Presented at Annual European Congress of Rheumatology EULAR 2006, Amsterdam, Netherlands, June 2006)
13. Garin CM, Strange C, Silver RM, Highland KB. Multivariable correlates of and limitations to the six-minute walk test (6MWT) in scleroderma-interstitial lung disease, scleroderma-pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. (Presented at Professor E. Carwile LeRoy Memorial International Workshop on Scleroderma, Tokyo, Japan, May 2007; **Winner Travel Scholarship from Scleroderma Clinical Trials Consortium**)
14. Highland KB, Gilkeson G, Bogatkevich G, Silver RM. Peroxisome proliferator-activated receptor gamma (PPAR- γ) expression in scleroderma interstitial lung disease. (Presented at Professor E. Carwile LeRoy Memorial International Workshop on Scleroderma, Tokyo, Japan, May 2007; **Winner Travel Scholarship from Scleroderma Clinical Trials Consortium**)
15. Bogatkevich GS, Ludwicka-Bradley A, Highland KB, Hant F, Nietert PJ, Singleton CB, Feghali-Bostwick C, Silver, M. Hepatocyte growth factor down regulates expression of CTGF in Caucasian, but not in African American scleroderma lung fibroblasts via two distinct signaling pathways. (Presented at Professor E. Carwile LeRoy Memorial International Workshop on Scleroderma, Tokyo, Japan, May 2007; **Winner Travel Scholarship from Scleroderma Clinical Trials Consortium**)
16. Garin MC, Chumney EC, Simpson KN, Highland KB. Cost-utility of treatments for pulmonary arterial hypertension. *Chest* 2007; 132:631-632b
17. Kalluri M, Sahn SA, Highland KB. The clinical profile of patients with PL-12 antibody. *Chest* 2007; 132:456b

18. Baughman RP, Engel, PJ, Lower EE, Highland KB, Judson MA. Sarcoidosis associated pulmonary arterial hypertension (SAPH): characteristics of patients enrolled in a prospective, open label trial of inhaled iloprost. *Chest* 2007; 132:482a
19. Lewis S, Silver R, Highland K, Shaftman S, Singleton B, Bogatkevich G. Cytokines in bronchoalveolar lavage fluid from SSc-ILD patients with and without alveolitis. *Arthritis and Rheumatism* 2008

Original Research:

1. Highland KB, Retalis P, Coppage L, Schabel SI, and Judson MA. Is There an Anatomic Explanation for Chest Pain in Patients with Pulmonary Sarcoidosis? *Southern Medical Journal* 1997; 90:922-14.
2. Highland KB, Strange C, Mazur J, Simpson KN. Treatment of pulmonary arterial hypertension: a preliminary decision analysis. *Chest* 2003; 124: 2087-92 **(Received editorial comment 2045-8)**
3. Highland KB, Strange C, Heffner JE. Long term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease: a meta-analysis. *Annals of Internal Medicine*. 2003; 138:969-973 **(Received editorial comment 1001-1002)**
4. Heffner JE, Highland KB, Brown LK. A meta-analysis derivation of continuous likelihood ratios for diagnosing pleural fluid exudates. *American Journal Respiratory and Critical Care Medicine*. 2003; 167:1591-1599
5. Bogatkevich GS, Ludwicka-Bradley A, Highland KB, Hant F, Nietert PJ, Feghali-Bostwick CA, Singleton CB, Silver RM: Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African-Americans: Possible role in systemic sclerosis. *Arthritis and Rheumatism*. 2007; 56:2432-2442
6. Benza RL, Barst RJ, Galie N, Frost A, Lawrence EC, Langleben D, Girgis RE, Highland KB, Strange C, Black CM, Badesch DB, Rubin L, Fleming T, Naeije R. Sitaxsentan for the treatment of pulmonary arterial hypertension: a one year, prospective, open-label observation of outcome and survival. *Chest* 2008; 134: 775-82
7. Bogatkevich GS, Ludwicka-Bradley A, Highland KB, Hant F, Nietert PJ, Singleton CB, Silver RM. Down-regulation of collagen and connective tissue growth factor expression with hepatocyte growth factor in lung fibroblasts from white scleroderma patients via two signaling pathways. *Arthritis and Rheumatism* 2007; 56:3468-3477

8. Distler O, Behrens F, Pittrow D, Huscher D, Denton CP, Foeldvari I, Humbert M, Matucci-Cerinic M, Nash P, Opitz CF, Rubin LJ, Seibod JR, Furst DE, for the EPOSS-OMERACT Group. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. *Arthritis Rheum (Arthritis Care & Research)* 2008; 59:867-875.
9. Garin MC, Highland KB, Silver RM, Strange C. Limitations to the Six-Minute Wal Test in Interstitial Lung Disease and Pulmonary Hypertension in Scleroderma. *J Rheum* 2009; in press

Case Reports:

10. Highland KB, Pantasari MW, Judson MA. Pharyngitis, Splenomegaly, Hilar, and Peripheral Adenopathy in a 29-Year-Old Man with Acute Hypoxic Respiratory Failure. *Chest* 2001; 119: 1586-1589.
11. Highland KB, Flume PA. A 12-Year-Old-Girl with Dyspnea and a Normal Chest Radiographic Finding. *Chest* 2001; 120:1372-76.
12. Highland KB, Flume PA. A "Story of a Woman with Cystic Fibrosis." *Chest* 2002; 121:1704-1707 **(Received editorial comment 1392-93)**
13. Ahmed SH, Aziz T, Cochran J, Highland KB. Use of extracorporeal membrane oxygenation in a patient with diffuse alveolar hemorrhage. *Chest* 2004; 126: 305-309 **(Received editorial comment 9-10)**
14. Mainie I, Tutian R, Agrawal A, Hila A, Highland KB, Adams DB, Castell DO. Fundoplication eliminates chronic cough due to non-acid reflux identified by impedance pH monitoring. *Thorax* 2005; 521-3.
15. Gay SE, Ankney N, Cochran JB, Highland KB. Critical Care Challenges in the Adult ECMO Patient. *Dimensions of Critical Care Nursing* 2005; 24:157-162.
16. Kalluri M, Sahn SA, Highland KB. Chronic dyspnea and severe obstruction after pneumonectomy: postpneumonectomy syndrome. *Am J Med Sci* 2008; 336:530-531.

Electronic Media:

17. Highland KB. Supraesophageal complications of gastroesophageal reflux disease. *PCCU* 2003;17, lesson 21
http://www.chestnet.org/education/online/pccu/vol17/lessons21_22/

18. Highland KB. Management of pulmonary hypertension in the connective tissue disease. PCCU 2008;22, lesson 18
http://www.chestnet.org/education/online/pccu/vol17/lessons21_22/

Book chapters, Monographs and Invited Publications:

19. Heffner JE, Highland KB. Chronic Obstructive Pulmonary Disease in Geriatric Critical Care. Critical Care Clinics. 2003; 19: 713-27.
20. Sutherland ER, Highland KB Inhaled corticosteroids in chronic obstructive pulmonary disease. Annals of Internal Medicine. 2003; 139: 864-5.
21. Highland KB. Cough. In: Epstein and Hansen-Flaschen, Ed. MKSAP (Medical Knowledge Self-Assessment Program) 13: Pulmonary Medicine and Critical Care. Philadelphia, PA: ACP-ASIM 2004; 1-3
22. Highland KB. Dyspnea. In: Epstein and Hansen-Flaschen, Ed. MKSAP (Medical Knowledge Self-Assessment Program) 13: Pulmonary Medicine and Critical Care. Philadelphia, PA: ACP-ASIM 2004; 3-4
23. Highland KB. Pulmonary rehabilitation. In: Epstein and Hansen-Flaschen, Ed. MKSAP (Medical Knowledge Self-Assessment Program) 13: Pulmonary Medicine and Critical Care. Philadelphia, PA: ACP-ASIM 2004; 10
24. Highland KB. Inhaled corticosteroids in COPD: Is there a long-term benefit? Current Opinion in Pulmonary Medicine 2004;10:113-119
25. Strange C, Highland KB. Interstitial Lung Disease in the Connective Tissue Disease Patient. Clinics in Chest Medicine. 2004; 25: 549-59.
26. Highland KB, Heffner JE. Pleural effusion in interstitial lung disease. Current Opinion in Pulmonary Medicine 2004; 10: 390-6
27. Highland KB. Giant cell interstitial pneumonitis caused by cobalt exposure. In: Baughman and du Bois, Ed. Diffuse Lung Disease: a practical approach. Oxford University Press, New York, NY 2004; 277-278.
28. Highland KB. Respiratory involvement in inflammatory bowel disease. In: Baughman and du Bois, Ed. Diffuse Lung Disease: a practical approach. Oxford University Press, New York, NY 2004; 278-280
29. Highland KB. Chronic beryllium disease In: Baughman and du Bois, Ed. Diffuse Lung Disease: a practical approach. Oxford University Press, New York, NY 2004; 280-282
30. Kirby RR, Lobato EB, Highland KB. Extracorporeal membrane oxygenation and pulmonary disease. Chest. 2005; 127:413-414.

31. Highland KB, Silver RM. Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study. *Current Rheumatology Reports* 2005; 7:135-141
32. Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. *Current Opinion in Pulmonary Medicine* 2005; 11: 451-455.
33. Highland KB, Silver RM. New developments in scleroderma interstitial lung disease. *Current Opinion in Rheumatology* 2005; 17:737-745
34. Highland KB, Harding SM. GERD-Related Lung Disease. *Practical Gastroenterology* 2005; XXIX:74-80
35. Highland KB, Garin MC, Brown KK. The spectrum of scleroderma lung disease. *Seminars in Respiratory Critical Care Medicine* 2007; 28: 418-429
36. Ostojic P, Cerinic MM, Silver R, Highland K, Damjanov N. Interstitial lung disease in systemic sclerosis. *Lung* 2007; 185:211-20
37. Highland KB. Pulmonary arterial hypertension. *Am J Med Sci* 2008; 335:40-45
38. Highland KB, Gilkeson G. Pulmonary hypertension in systemic lupus erythematosus. *Advances in Pulmonary Hypertension*. 2008; 7:280-285.
39. Kowal-Bielecka O, Kowal K, Highland KB, Silver RM. Bronchoalveolar lavage fluid in scleroderma interstitial lung disease: technical aspects and clinical correlations: review of the literature. *Sem Arthritis Rheum*; 2009; in-press

COMMUNITY SERVICE

Aloha Medical Mission	11/2000.
Northern Samar, Philippines.	
Crisis Ministries	2002-2008
Charleston, SC	